Clinical trial
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
NCT00408447 · Columbia University, Other · Active, not recruiting
Key facts
| NCT number | NCT00408447 |
|---|---|
| Title | Stem Cell Transplant in Sickle Cell Disease and Thalassemia |
| Official title | Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia |
| Lead sponsor | Columbia University, Other |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease, Beta Thalassemia |
| Intervention type | Drug, Procedure |
| Interventions | Busulfan, Fludarabine, Alemtuzumab, Allogeneic stem cell transplant |
| Enrollment | 53 |
| Start date | Sep 1, 2004 |
| Primary completion | Feb 1, 2025 |
| Completion | Feb 1, 2025 |
| First posted | Dec 7, 2006 |
| Last update posted | Jun 13, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: